The partnership covers atrasentan (a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases) and BION-131 (an anti-APRIL monoclonal antibody being evaluated in a phase 1/2 trial for IgA nephropathy) across the People’s Republic of China, Hong Kong, Macau, Taiwan and Singapore.
“Formation of this joint venture allows Chinook to expand our global reach and establish a strong presence in China by partnering with investors who are experienced in company formation, drug development and commercialization in the region,” said Eric Dobmeier, president and CEO of Chinook Therapeutics, a Seattle-headquartered company focused on the discovery, development and commercialization of precision medicines for kidney diseases.
“Chronic kidney disease is a major public health concern in China, affecting over 10% of the population, including several million patients with IgAN. Working with SanReno will expand Chinook’s access to Chinese patient populations, key opinion leader networks and on-the-ground operational support to accelerate enrollment and regulatory approval of our programs globally.
“The establishment of SanReno is a testament to our commitment to making dialysis and transplant unnecessary for people living with kidney disease around the world.”
Under the terms of the joint venture, Chinook has granted SanReno exclusive rights to develop and commercialize atrasentan and BION-1301 in exchange for 50% ownership of SanReno. An investor syndicate led by Frazier Healthcare Partners and Pivotal bioVenture Partners China, along with existing Chinook investors Versant Ventures and Samsara BioCapital, has invested $40m in exchange for the remaining 50% ownership of SanReno.
In addition to its equity stake, Chinook is entitled to receive progress-dependent milestone payments and royalties with respect to atrasentan and BION-1301.
SanReno will be responsible for all development, manufacturing and commercialization costs for atrasentan and BION-1301, while Chinook will supply clinical trial material and technical support until manufacturing technology transfer has been completed. Chinook and the investor syndicate have an option to participate in future investment rounds for SanReno. Chinook and SanReno also have reciprocal rights of first negotiation in their respective territories for certain future kidney disease products developed or in-licensed by either company.
Chinook retains full rights to atrasentan and BION-1301 outside of the areas covered by the agreement.